The phosphatidylinositol 3-kinase (PI3K) signaling pathway is upregulated in cancer. PIK3CA, the gene coding for the catalytic subunit p110␣ of PI3K, is mutated in Ϸ30% of tumors of the prostate, breast, cervix, and endometrium. The most prominent of these mutants, represented by single amino acid substitutions in the helical or kinase domain, show a gain of enzymatic function, activate AKT signaling, and induce oncogenic transformation. We have carried out a genetic and biochemical analysis of these hot-spot mutations in PIK3CA. The results of this study suggest that the helical and kinase domain mutations trigger gain of function through different mechanisms. They show different requirements for interaction with the PI3K regulatory subunit p85 and with RAS-GTP. The gain of function induced by helical domain mutations is independent of binding to p85 but requires interaction with RAS-GTP. In contrast, the kinase domain mutation is active in the absence of RAS-GTP binding but is highly dependent on the interaction with p85. We speculate that the contrasting roles of p85 and RAS-GTP in helical and kinase domain mutations reflect two distinct states of mutated p110␣. These two states differ in mutation-induced surface charges and also may differ in conformational properties that are controlled by interactions with p85 and RAS-GTP. The two states do not appear mutually exclusive because the helical and kinase domain mutations act synergistically when present in the same p110␣ molecule. This synergism also supports the conclusion that the helical and kinase domain mutations operate by two different and independent mechanisms.
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cancer ͉ molecular mechanisms ͉ p85 ͉ RAS ͉ AKT P hosphatidylinositol 3-kinases (PI3Ks) phosphorylate phosphatidylinositols at the 3Ј position of the inositol ring, generating second messengers that control cellular activities and properties, including proliferation, survival, motility, and cell shape. Mutations that block PI3K function disrupt these processes (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . PI3Ks form a family that is divided into three classes, differing in structure, substrate preference, tissue distribution, mechanism of activation, and, ultimately, function (12) (13) (14) (15) (16) . For the regulation of cell proliferation and in tumorigenesis, the most important PI3K proteins are those of class IA, notably the catalytic subunit p110␣ and its associated regulatory subunits (p85␣, p55␣, p50␣, p85␤, and p55␥).
p110␣ contains an N-terminal p85-binding domain (p85BD), a Ras-binding domain (RBD), a protein-kinase-C homology-2 (C2) domain, a helical domain, and a C-terminal kinase domain (17) . p110␣ is constitutively associated with regulatory subunits, of which p85␣ is the best studied (herein referred to as p85). p110␣ and p85 exist in the cell as a heterodimeric complex. In quiescent cells, p85 stabilizes p110␣ and inactivates PI3K activity (18) . Upon growth factor stimulation, receptor tyrosine kinases (RTKs) undergo autophosphorylation, creating binding sites for Src homology 2 (SH2) domain-containing proteins. The SH2 domains of p85 bind to phospho-YxxM motifs in RTKs (19) . This binding relieves the inhibition of p110␣ and mediates the recruitment of PI3K to the plasma membrane. Direct interaction between GTP-bound Ras and p110␣ through the RBD further augments the activity of p110␣ (20) (21) (22) .
p110␣ shows mutations in Ϸ30% of tumors of the prostate, breast, cervix, and endometrium (Catalog of Somatic Mutations in Cancer, www.sanger.ac.uk/genetics/CGP/cosmic). Genetic, biochemical, and cell-based analyses have shown that such mutated p110␣ functions as an oncoprotein playing an important role in tumorigenesis (1, 10, 23, 24) . The most frequently occurring mutations, E542K, E545K, and H1047R, increase enzymatic activity, stimulate AKT (protein kinase B) signaling, induce growth factor and anchorage independent growth in culture, and cause tumors in vivo (10, (25) (26) (27) (28) (29) .
In this article, we examine the biochemical and celltransforming activities of several mutant forms of p110␣ in chicken embryonic fibroblasts (CEFs). We demonstrate that helical and kinase domain mutations operate by two different and independent gain-of-function mechanisms. Our results show that (i) gain of function by E542K and E545K is highly dependent on RAS-GTP binding, (ii) gain of function by H1047R is likely dependent on allosteric change mediated by p85, and (iii) this allosteric change triggered by H1047R may mimic RAS-GTP binding, making this mutant independent of an interaction with RAS-GTP.
Results

Helical Domain and Kinase Domain Mutations Act Synergically in Cell
Transformation. The modeled structure of p110␣ suggests that the helical domain mutations and kinase domain mutation map to the surface of the protein and affect protein-protein or domaindomain interactions (24, 30) . We hypothesized that the spatially separated kinase domain and helical domain mutations may trigger gains of function through different molecular mechanisms. To test this hypothesis, we examined the properties of the double mutants E542K/E545K, E542K/H1047R, and E545K/ H1047R ( Fig. 1 A and B) . These double mutants transformed CEFs more efficiently, inducing the foci of transformed cells earlier and in greater number than single hot-spot mutants. The increase in activity was additive when both mutations were in the helical domain. However, combining helical and kinase domain mutations within the same p110␣ molecule had a clear synergistic effect and generated a potently transforming protein. The product of PI3K, PIP3, mediates the activation of several signaling pathways, including that of AKT (31) . We tested the cellular phospho-AKT level in CEFs expressing the p110␣ double mutants under the condition of serum starvation. Although the total AKT levels were down-regulated in CEFexpressing double mutants E542K/H1047R or E545K/H1047R, the phospho-AKT levels were Ϸ1,000-fold higher than in CEFs expressing the single mutants E542K, E545K, or H1047R (normalized to the protein levels of p110␣). The highly up-regulated AKT signals detected in CEFs expressing E542K/H1047R or E545K/H1047R correspond to the strong cell-transforming activity of these mutants (Fig. 1C) . In contrast, a combination of the two helical domain mutations E542K and E545K conferred a moderate increase in the transforming activity of the protein and enhanced AKT signaling slightly, compared with E542K and E545K alone. Biochemical and structural studies support the proposal that the helical domain mutations E542K and E545K relieve an inhibitory interaction between the N-terminal SH2 domain of p85 and the helical domain of p110␣ (32, 33) . To examine the effect of p85 binding on mutant activity, we eliminated the binding of p110␣ to p85 by deleting the 72 N-terminal amino acids from all p110␣ constructs. The truncated p110␣ proteins no longer interacted with p85, and truncated and full-length p110␣ proteins were expressed at approximately equal levels (Fig. 2C) . The elimination of p85 binding had a minor effect on the transforming activity of the helical domain mutations, but completely abolished transformation induced by the H1047R kinase domain mutation ( Fig. 2 A and B) . In the absence of p85 binding, WT p110␣ gained weak transforming activity ( Fig. 2 A and B) . This observation is in agreement with previous studies (28) and probably reflects the removal of a p85-mediated inhibitory effect.
Cells expressing mutant constructs that fail to interact with p85, including truncated E542K, E545K, and H1047R, show constitutive phosphorylation of AKT and S6K, albeit at lower levels than cells expressing the full-length proteins (Fig. 2C ). Because truncated H1047R fails to transform cells, an upregulated AKT pathway alone appears to be insufficient for PI3K-induced oncogenic transformation. Our results suggest . that an unknown process dependent on p85 binding plays a critical role in H1047R oncogenicity.
We also examined the effect of the N-terminal truncation on the double mutants E542K/H1047R and E545K/H1047R. These constructs show transforming activity with the same potency as that of the single helical domain mutants E542K and E545K ( Fig.  3 A and B) . Activation of AKT also corresponds to the levels induced by single helical domain mutants (Fig. 3C) . The synergistic effect that is seen in the full-length double mutant is lost in the deletions, further suggesting that p85 binding is essential for the gain of function associated with H1047R.
RAS Binding Is Essential for Transformation by Helical Domain Mutants of p110␣.
Previous studies have shown that a point mutation in the RBD of p110␣, K227E, blocks the interaction of p110␣ and RAS and abrogates the ability of RAS to activate PI3K (21) . We constructed a series of RAS-binding mutants of p110␣ proteins changing lysine 227 to glutamate. We then determined the transforming activities of these mutants in focus assays (Fig. 4 A  and B) . The K227E mutation does not affect oncogenic transformation induced by the kinase domain mutant H1047R, but completely abolishes the transforming activities of the helical domain mutants E542K and E545K. The mutant constructs were expressed at approximately equal levels (Fig. 4C) . These differences in transforming potency are in agreement with the effects on AKT signaling. K227E/H1047R transforms cells and leads to constitutive activation of AKT signaling, albeit at a lower level than H1047R. In contrast, K227E/E542K and K227E/E545K fail to transform cells and do not induce constitutive activation of AKT signaling.
To confirm the effect of K227E on RAS-mediated activation, we tested the AKT signaling in CEFs transfected with a p110␣ expression vector only and CEFs cotransfected with p110␣ and HRAS (G12V) expression vectors (Fig. 5) . Our results show that the WT and the hot-spot mutants of p110␣, when coexpressed with HRAS (G12V), lead to activation of both ERK and AKT. In contrast, CEFs expressing the RBD mutants of p110␣ failed to activate AKT, although ERK activation was detected. The basal level of AKT phosphorylation in these cells is probably due to endogenous PI3K activity. Because of the short exposure time, the level of AKT phosphorylation at T308 in cells expressing E542K, E545K, and K227E/H1047R is not shown in the Western blot of Fig. 5 .
In the previous section, we showed that WT p110␣ with a deletion in the p85-binding domain gained transforming activity and constitutive lipid kinase activity possibly by the removal of an inhibitory interaction between p85 and p110␣. To test whether the gain of function by this truncated WT p110␣ depends on RAS binding, we introduced the K227E mutation in this construct. CEFs expressing this double mutant did not undergo transformation (data not shown) and did not show the up-regulation of AKT signaling seen with this mutant in the presence of Ras binding (Figs. 2C and 4C ). These results suggest that RAS-mediated activation is indispensable for p110␣ activation.
The H1047R Mutation Can Substitute for RAS Binding.
Because the cell-transforming activity of H1047R is independent of RAS binding, we speculated that an active conformation triggered by the H1047R mutation might mimic the activation mediated by binding to RAS. We therefore constructed the triple mutants K227E/E542K/H1047R and K227E/E545K/H1047R. Expression of these two mutant forms of p110␣ in CEFs resulted in potent and efficient transformation (Fig. 6B) . The quantitative aspects of this transformation as measured in focus assays are similar to those determined with E542K/H1047R or E545K/H1047R, leading to focus formation within 7 days (Fig. 6A ). In agreement with this transforming activity, AKT signaling in these cells is constitutively up-regulated, similar to the levels seen in CEFs expressing E542K/H1047R or E545K/H1047R (Fig. 6C) .
Discussion
Gain-of-function and oncogenic activity make the cancerspecific mutants of p110␣ ideal therapeutic targets. However, to take advantage of this unique situation and design mutantspecific interventions, it is necessary to ascertain the molecular mechanisms responsible for the gain of function in the p110␣ mutants. We used genetic and functional analyses to gain insight into mutant mechanisms. As detailed below, our conclusions are in accord with recent structural data on p110␣ (33, 34) . The three hot-spot mutations in PIK3CA account for Ϸ80% of the mutated p110␣ proteins found in diverse cancers (Catalog of Somatic Mutations in Cancer, www.sanger.ac.uk/genetics/ CGP/cosmic). These mutations map to two functionally and structurally distinct domains of p110␣. E542K and E545K are localized to the helical domain, and H1047R resides in the kinase domain. Mapping of these mutations in two distinct functional domains suggests that helical and kinase domain mutations operate by different molecular mechanisms. A simple test that could support the hypothesis of two molecular mechanisms is to introduce two mutations concurrently in the same protein.
The tests of such double mutants revealed a strong synergism of the helical kinase domain combination of mutations, but only simple additivity for the helical domain double mutant. These data are best explained by the two-mechanism proposal, but they do not rule out the possibility of a single mechanism that is greatly enhanced by a combination of mutations in different domains. The E545K/H1047R double mutant has been found to be naturally occurring in human cancer (6) . This natural occurrence may reflect the strong selective growth advantage conferred on cells by this mutant combination.
The properties of mutant p110␣ that lack either p85 or RAS binding provide more compelling evidence for two different mechanisms triggered by helical and kinase domain mutations, respectively. The p110␣ protein occurs in the cell as a heterodimer bound to p85. The p85 subunit stabilizes p110␣ but also inhibits the lipid kinase activity of p110␣. We generated p110␣ constructs that are defective in p85 binding by deleting the 72 N-terminal amino acids of p110␣. These constructs are stable, are efficiently expressed, and fail to interact with p85 as determined by coimmunoprecipitation. The defect in p85 binding has contrasting consequences in helical and kinase domain mutants, leaving the former active, but completely abolishing the transforming activity of the latter. Phosphorylation of AKT was, however, not completely inhibited in cells expressing H1047R that lacked p85 binding. WT p110␣ with the 72 N-terminal amino acid truncation showed modest gain of function and became weakly oncogenic.
Previous biochemical and structure modeling studies have provided evidence for an interaction between the N-terminal SH2 domain of p85 (N-SH2) and the helical domain of p110␣ (32, 33) . This interaction is responsible for the p85-induced inhibition of p110␣. The helical domain mutations may interfere with this p85-p110␣ interaction and thus remove the inhibition.
Co-expressed with HRAS (G12V)
. Fig. 5 . RAS-binding mutation of p110␣ abolishes the activation by HRAS (G12V). CEFs were transfected with the p110␣ expression vector only or cotransfected with p110␣ and HRAS (G12V) expression vectors. Cells were maintained in a nutrient medium containing 3% FBS and 1% chicken serum and were then harvested and probed with the indicated antibodies by Western blotting.
Serum free condition A weakened interaction between N-SH2 and p110␣ by the helical domain mutations E542K and E545K also is suggested by the failure of the lipid kinase activity of these mutants to become activated by the phosphorylated insulin receptor substrate, in contrast to WT and H1047R p110␣ (35) . Despite the disconnection from upstream input, the N-terminally truncated E542K and E545K induced constitutive activation of AKT. The Nterminally truncated helical domain mutations show significantly higher oncogenic potency than the truncated WT p110␣. Because both have lost p85 binding, the difference in oncogenic potency then suggests an effect of the helical domain mutations that goes beyond interference with the p85 interaction. PI3K is an important RAS effector and has a role in mediating the proliferative and survival functions of RAS (20, 21) . Direct interaction between GTP-bound RAS and p110␣ mediated by the RBD augments the activity of p110␣ (22) possibly by inducing a conformational change at the substrate-binding site (36) . Disrupting the interaction between p110␣ and RAS inhibits the in vitro transformation of mouse embryo fibroblasts by oncogenic KRAS (G12V) (37) . Because the product of PI3K, PIP3, can activate RAS by stimulating the GEF activity of SOS (38) , we postulated that PI3K-RAS binding also may play a critical role in oncogenic transformation by PI3K. We disabled RAS binding by introducing a point mutation K227E and found again contrasting effects on helical and kinase domain mutations, but opposite to the effects seen with deleted p85 binding. In the case of disabled RAS binding, transforming ability and AKT activation by the helical domain mutations were abolished, whereas those by the kinase domain mutation H1047R remained unaffected. The H1047R mutation could even rescue the helical domain mutants that are unable to bind RAS and could restore their activity to the same levels as detected in the synergistic double mutants E542K/H1047R and E545K/H1047R. The gain of function induced by H1047R is independent of RAS binding, whereas that of E542K and E545K requires RAS interaction. We hypothesize that H1047R induces an allosteric change of p110␣ that mimics RAS-GTP binding. A schematic summary of mutant properties is presented in Fig. 7 .
Our data and conclusions are in broad agreement with the recently published crystal structure of the p110␣-p85 complex (34) . In this publication, the interaction between the N-SH2 domain of p85 and the helical domain is modeled, and the model allows for the possibility that this interaction could be weakened by the helical domain mutations of p110␣. However, the model does not definitely exclude a possible effect of the helical domain mutations on the interaction with another p110␣-binding partner. The kinase domain mutation H1047R maps close to the activation loop and may affect the conformation of the loop, altering the interaction with the substrate. Previous structural studies on the p110␥-RAS complex also have demonstrated a change in the conformation of the substrate-binding site as a result of RAS binding (36) . These data are consistent with our hypothesis that H1047R activates p110␣ by inducing a conformational shift that is similar to that caused by RAS. The crystal structure of the p110␣-p85 complex also reveals an unexpected interaction between the p85-binding domain (adaptor-binding domain) and the kinase domain. This interaction might be important for the active conformation induced by H1047R and could explain the sensitivity of H1047R to a loss of p85 binding.
Our studies strongly suggest that helical and kinase domain mutations trigger a gain of p110␣ function by different molecular mechanisms. Helical domain mutations function independently of p85, but require RAS. The kinase domain mutation H1047R requires p85, but not RAS (Fig. 7) . The two gain-of-function states represented by helical and kinase domain mutations differ in surface charge and most likely reflect different conformational changes mediated by p85 or RAS, respectively. These conformational changes may make it possible to identify mutantspecific small-molecule inhibitors of p110␣. Such inhibitors will not affect the WT enzyme and, therefore, will have superior therapeutic properties as anticancer drugs.
Materials and Methods
Plasmid Construction. The construction of the pBSFI vector KOZ-cp3k encoding WT, E542K, E545K, and H1047R chicken p110␣ has been described previously (27, 39) . The double mutants were constructed by using the QuikChange site-directed mutagenesis kit (Stratagene) with E542K as the template to generate E542K/H1047R and with E545K as the template to generate E545K/ H1047R. The primers used were described previously (27) . To generate E542K/E545K, E542K was used as the template, and the primer used was: E542K/E545K, 5Ј-CGA GAT CCT TTG TCT AAA ATC ACT AAG CAA GAG-3Ј (only the forward primer is listed). The construction of pBSFI-⌬72-cp3k (encoding p110␣ with a deletion of the first 72 amino acids) has been described previously (39) . The mutant constructs containing an E542K, E545K, or H1047R substitution were generated by using the QuikChange site-directed mutagenesis kit (Stratagene). To generate the K227E mutant constructs, the pBSFI vector KOZ-cp3k encoding WT, E542K, E545K, H1047R, E542K/E545K, E542K/ H1047R, and E545K/H1047R was used as a template, and the primer used was: K227E, 5Ј-GCT GAA GCA ATT AGG GAG AAA ACA CGA AGT ATG-3Ј (only the forward primer is listed). The mutated genes were subsequently cloned into the avian retrovirus vector RCAS.Sfi (40) . All mutations were confirmed by sequencing.
Cell Culture and Transfection. Fertilized chicken eggs (white Leghorn) were obtained from Charles River Breeding Laboratories. Preparation and cultivation of primary CEFs have been described previously (41) . CEFs were maintained in Ham's F-10 medium (Sigma-Aldrich) supplemented with 7% FBS (Sigma-Aldrich), 5% chicken serum (Sigma-Aldrich), 1x MEM vitamin solution (Sigma-Aldrich), 8 mg/liter folic acid, and 1% L-glutamine-penicillinstreptomycin solution (Sigma-Aldrich) at 37°C in 5% CO 2. Cells were plated at 80% confluence in 100-mm tissue culture and were then transfected with relevant RCAS vectors by using the dimethyl sulfoxide/Polybrene method (42) . CEFs were passaged three times to ensure the high infection rate by RCAS viruses. After three passages, the cells were harvested for further analysis. For serum starvation, CEFs were first maintained in Ham's F-10 medium with 0.25% FBS and 0.05% chicken serum for 40 -44 h, followed by an additional 2 h in Ham's F-10 medium. They were then harvested for protein analyses.
Transformation Assays. DNA was transfected into CEFs by using either the Lipofectamine reagent (Invitrogen) or the dimethyl sulfoxide/Polybrene method (42) . Transfected cells were fed every other day with nutrient agar and then stained with crystal violet. After incubation of cells under nutrient overlay, the foci of transformed cells were counted Ϸ2 weeks after transfection. For focus growth curves, the foci of transformed cells were counted every other day. Fig. 7 . A schematic summary of mutant properties. p85BD, p85-binding domain; RBD, Ras-binding domain; C2, C2 domain. The approximate locations of the point mutations are indicated by inverted triangles, and the deletion in the p85BD is marked by a truncated alias of the p85BD. Cell-transforming activity is qualitatively denoted by ϩ and Ϫ, and synergistic activity is denoted by ϩ!.
